Evidence map›Paper›PMID 40698821›Full record

ArticleAntimicrobial agents and chemotherapy2025

A cap-dependent endonuclease inhibitor acts as a potent antiviral agent against La Crosse virus infection.

Kei Konishi, Yoshiyuki Taoda, Manabu Igarashi, Takao Shishido, Kazuya Yasuo, William W Hall, Yasuko Orba, Hirofumi Sawa, Michihito Sasaki, Akihiko Sato

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kei KonishiLaboratory for Drug Discovery & Disease Research, Shionogi & Co., Ltd., Osaka, Japan.ORCID 0009-0009-5751-863X
Yoshiyuki TaodaLaboratory for Medicinal Chemistry Research, Shionogi & Co., Ltd., Osaka, Japan.
Manabu IgarashiDivision of Global Epidemiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
Takao ShishidoLaboratory for Drug Discovery & Disease Research, Shionogi & Co., Ltd., Osaka, Japan.
Kazuya YasuoLaboratory for Medicinal Chemistry Research, Shionogi & Co., Ltd., Osaka, Japan.
William W HallInternational Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
Yasuko OrbaDivision of Anti-Virus Drug Research, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
Hirofumi SawaDivision of Anti-Virus Drug Research, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
Michihito SasakiInstitute for Vaccine Research and Development (HU-IVReD), Hokkaido University, Sapporo, Japan.ORCID 0000-0003-1607-2175
Akihiko SatoLaboratory for Drug Discovery & Disease Research, Shionogi & Co., Ltd., Osaka, Japan.ORCID 0000-0001-6625-1679

Funding

Japan Agency for Medical Research and Development JP223fa627005, JP23wm0125008Japan Science and Technology Agency JPMJMS2025
6 · The paper itself

Abstract

La Crosse virus (LACV) infection, the causative agent of La Crosse encephalitis, can lead to severe neurological symptoms and sequelae, particularly in children. Despite annual reports of neurologically symptomatic cases, no effective treatment has yet been established. Bunyaviruses, including LACV, utilize a cap-snatching mechanism for transcription, with a cap-dependent endonuclease (CEN) serving as a promising target for antiviral treatment. Specifically, we now demonstrate that a CEN inhibitor, carbamoyl pyridone carboxylic acid (CAPCA)-1, exhibits potent anti-LACV activity

Indexed as

Antiviral AgentsEncephalitis, CaliforniaEndonucleasesEnzyme InhibitorsLa Crosse virusPyridonesAmidesAnimalsChlorocebus aethiopsHumansMicePyrazinesRibavirinVero CellsViral LoadVirus ReplicationAmidesAntiviral AgentsEndonucleasesEnzyme InhibitorsfavipiravirPyrazinesPyridonesRibavirinantiviralsbunyavirusescap-dependent endonucleaseLa Crosse virus

Identifiers

PMID40698821
PMCPMC12406681

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.